Olema Pharmaceuticals Quarterly Balance Sheet
NASDAQ: OLMAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Olema Pharmaceuticals financial position
As of Jun 30, 2026, Olema Pharmaceuticals reported total assets of $486.6 million, up 27.4% from a year earlier against total liabilities of $56.0 million. Shareholders' equity stood at $430.6 million, or 88.5% of assets. The company held $48.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.86, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Olema Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 48.60M | 52.55M | 48.30M | 35.26M | 52.47M | 50.64M | 139.48M | 35.89M | 16.89M | 33.72M | 68.54M | 117.41M |
| Short-Term Investments | 412.47M | 452.80M | 457.14M | 293.70M | 309.44M | 342.07M | 294.61M | 178.88M | 222.21M | 215.26M | 193.27M | 159.49M |
| Total Current Assets | 469.88M | 513.23M | 515.45M | 334.33M | 367.73M | 396.66M | 438.47M | 217.99M | 242.19M | 252.09M | 266.51M | 282.01M |
| Property, Plant & Equipment | 382.00K | 356.00K | 274.00K | 486.00K | 560.00K | 653.00K | 746.00K | 849.00K | 945.00K | 1.03M | 968.00K | 1.06M |
| Total Assets | 486.58M | 530.64M | 533.43M | 352.45M | 382.00M | 409.64M | 450.98M | 230.17M | 254.56M | 263.69M | 276.94M | 292.80M |
| Accounts Payable | 1.67M | 3.72M | 9.25M | 3.47M | 934.00K | 151.00K | 4.46M | 2.69M | 4.35M | 7.66M | 2.70M | 2.21M |
| Total Current Liabilities | 53.01M | 47.17M | 51.80M | 41.66M | 33.16M | 26.06M | 41.76M | 30.70M | 26.54M | 26.22M | 21.62M | 15.97M |
| Total Liabilities | 56.01M | 50.17M | 54.87M | 44.97M | 36.77M | 26.19M | 42.02M | 31.26M | 27.39M | 27.38M | 23.05M | 17.66M |
| Shareholders' Equity | 430.56M | 480.48M | 478.56M | 307.49M | 345.24M | 383.45M | 408.96M | 198.91M | 227.16M | 236.32M | 253.90M | 275.13M |
| Retained Earnings | -713.85M | -650.65M | -597.56M | -551.50M | -509.28M | -465.50M | -435.11M | -401.54M | -366.98M | -336.60M | -305.63M | -278.86M |
| Net Cash (Debt) | 461.07M | 505.35M | 505.44M | 328.96M | 361.91M | 392.71M | 434.09M | 214.76M | 239.10M | 248.98M | 261.81M | 276.90M |
| Shares Outstanding | 87.45M | 87.33M | 81.38M | 68.65M | 68.63M | 68.33M | 74.31M | 57.29M | 57.25M | 55.87M | 54.99M | 54.60M |
This table shows 12 quarterly periods of Olema Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow OLMA's reporting calendar. What is a balance sheet?